^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hairy Cell Leukemia |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/30/2022
Excerpt:
Hairy Cell Leukemia…SUGGESTED TREATMENT REGIMENS…Useful in Certain Circumstances…Vemurafenib + obinutuzumab…
